Recital 7, Regulation (EU) 2025/1466

In forcesince 22 Jul 2025

Suspected adverse reactions to a medicinal product are reported to the Eudravigilance database by means of individual case safety reports. The reports should be as complete as possible, but in order to ensure some standardisation of reports, minimum reporting requirements should apply in all cases.